VivoSeq
Infectious Disease

Gonorrhea

19

Pipeline Programs↗

3

Active Trials↗

10

Companies Involved↗

Gonorrhea is an emerging landscape with 19 programs across 10 companies. The most active players are Entasis Therapeutics, GSK, Glaxo Dba Glaxosmithkline. 7 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

85/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Entasis Therapeutics

1 program

Phase 2GSK logo

GSK

2 programs

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 3K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 3M

Melinta Therapeutics, Inc.

2 programs

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

16

clinical trials

Completed11 · 69%
Terminated2 · 13%
Active, not recruiting1 · 6%
Recruiting1 · 6%
Not yet recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of iStatis Gonorrhea Antigen Test by Trained Personnel at Near-Patient or Point-of-Care Settings
Recruiting·BbioLytical Laboratories·Preclinical·NCT07569900·650 enrolled
Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections
Active, not recruiting·—·Phase 3·NCT05766904·150 enrolled
A Preliminary Investigation to Determine the Utility of Using Metagenomic Analysis of Pharyngeal Samples Taken From Partners of Patients Diagnosed With Gonorrhoea to Identify Organisms, Antibiotics Resistance and Virulence Factors of Neisseria Species and the Impact of STI Prevention Strategies (4CMenB Vaccination and DoxyPEP)
Not yet recruiting·GGuy's and St Thomas' NHS Foundation Trust·N/A·NCT07671014·100 enrolled
Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea
Completed·MMelinta Therapeutics, Inc.·Phase 2·NCT01591447·60 enrolled
A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea
Completed·GSK logoGSK·Phase 3·NCT04010539·628 enrolled
A Study Evaluating Efficacy and Safety of CRO-SBT in the Treatment of Gonorrhea
Completed·XXiangbei Welman Pharmaceutical Co., Ltd·Phase 4·NCT04202068·113 enrolled
Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea
Completed·MMelinta Therapeutics, Inc.·Phase 3·NCT02210325·264 enrolled
Efficacy of Combination Therapies for Gonorrhea Treatment
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00926796·614 enrolled
Aztreonam for Pharyngeal Gonorrhea
Completed·UUniversity of Washington·Phase 2/3·NCT03867734·32 enrolled
Trial Comparing Ceftriaxone Plus Azithromycin Versus Ceftriaxone for the Treatment of Gonorrhea
Completed·IInstitute of Tropical Medicine, Belgium·Phase 4·NCT05027516·42 enrolled
Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02257918·180 enrolled
A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.
Completed·Pfizer logoPfizer·N/A·NCT05873751·1,307,378 enrolled
A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae
Completed·GSK logoGSK·Phase 2·NCT02294682·106 enrolled
A Randomized Crossover Study to Evaluate the Efficacy of Antibacterial Mouthwash in Preventing Pharyngeal Gonorrhea Among a High Risk Population
Completed·UUniversity of California, Los Angeles·Phase 2·NCT04966507·89 enrolled
Gent for Pharyngeal Gonorrhea (GC)
Terminated·UUniversity of Washington·Phase 2/3·NCT03632109·13 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)